Influenza virus particles viewed by a electron microskada, with additional color
John G / Imando / Kala
A dose of a long antiviral medicine reflects the promise of protection against all FLU Riots, progressing hope that it can protect the more vulnerable.
The flu kills thousands of people every year and the strong evolution of new variants may prompt the next pandemic. Each year, scientists have updated the flu vaccines to match the Influenza virus lines they expect to expand most of the weather in future flu. it vaccines Immune system prompt to produce antibodies that prevent virus from entering your cells.
Scientists are working on a Universal Flu vaccine That will protect against all the scars that attract people, but such a vaccine has limits.
“Although someone includes the first (approved) flu vaccine, it does not protect all, because people have different resistant resistance refers to resistance,” as Jeffrey SteinCEO of Biotech Cidara Company. For example, vaccines are usually less effective than older people or those with restricted resistance.
To answer this, Stein and his associated treats called CD388, with Zanamivir, an antiviral drug approved because of all infections caused by all people. Mostly zanamivir from the body within hours, but changed it to the chemical team in the months of the body, where it was quick to destroy the invasion of body viruses. “It doesn’t involve the immune system,” Stein said.
To test this, the team recruits 5000 people, 16 to 64, from the US and UK at the beginning of the 2024 season of the flu. None of the participants were more risky to flu-related complications or still received the flu vaccine that year. The team divides participants into four equal equal groups. Three received an injection of CD388 at a low, medium or high dose, while the remaining participants took a placebo.
About six months ago, researchers looked at how many participants have flu flu infections – flu symptoms are like a cough and fever.
While 33 people in the placebo group have a symptom flu, only eight people take a long dose of CD388 – about 76 percent reducing risk. Those in medium- and low-dosing groups have seen their risk of symptom infection cut by 61 percent and 58 percent, indeed. “All doses reflect important protection against flu disorder,” as Nicole DavarpanahChief Medical Officer in Cidara. Similar effects, such as gentleness on the site in injection, occurred in the treatment and placebo groups.
Knowing suggests that CD388 can provide a simple way to protect people than vaccines. “(Unlike vaccines, no need to be paired with surroundings and can be more effective in ‘bad preparation of desert, such as H5N1 suppenca, like H5N1 Supid, Penny Ward In the King’s College London. On the basis of the first data of Zanamivir, the flu strains also do not move them to resist, he said.
To clear, the procedure should work well with people who know badly responds to vaccination, like older people or not confidently with host residents. To check it, Davarpanah says the team plans a test of immunocompromised people aged 12 and older.
Stein said, instead of replacing vaccines, medicine may be the best partner with them – even if it is still tested. However the odds are timely Increases in doubt of vaccines. “It avoids the controversy that unfortunately associates with vaccines,” Stein said.
Topics: